HULUWA(SH:605199) Xin Lang Cai Jing·2025-10-30 13:00Company Overview - ST HuLuWa, established on June 22, 2005, and listed on the Shanghai Stock Exchange on July 10, 2020, is a high-tech enterprise engaged in the research, production, and sales of pharmaceuticals, with a strong competitive edge in the pediatric medicine sector [1] Financial Performance - For Q3 2025, ST HuLuWa reported revenue of 683 million yuan, ranking 49th out of 69 in the industry. The industry leader, Baiyunshan, achieved revenue of 61.606 billion yuan, while the industry average was 3.755 billion yuan [2] - The company's net profit for the same period was -7.5472 million yuan, placing it 56th in the industry. The top performer, Yunnan Baiyao, reported a net profit of 4.789 billion yuan, with the industry average at 447 million yuan [2] Profitability and Debt - As of Q3 2025, ST HuLuWa's debt-to-asset ratio was 73.72%, an increase from 68.11% year-on-year, significantly higher than the industry average of 32.81% [3] - The gross profit margin for Q3 2025 was 40.43%, down from 50.06% year-on-year and below the industry average of 52.44% [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 13.59% to 27,300, while the average number of circulating A-shares held per account increased by 15.73% to 14,700 [5] Executive Compensation - The chairman, Liu Jingping, received a salary of 1.4 million yuan in 2024, a decrease of 6,000 yuan from 2023 [4]